Multiple System Atrophy
4
Pipeline Programs
4
Companies
5
Clinical Trials
3 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 3 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
BiohavenVerdiperstat
TevaTEV-56286
TevaTEV-56286
TevaTEV-56286
Ionis PharmaceuticalsION464
Clinical Trials (5)
Total enrollment: 1,019 patients across 5 trials
Study of BHV-3241 in Participants With Multiple System Atrophy
Start: Jul 2019Est. completion: Jun 2022421 patients
Phase 3Completed
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
Start: Sep 2025Est. completion: May 2029200 patients
Phase 2Recruiting
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
Start: Oct 2024Est. completion: Sep 2027350 patients
Phase 2Recruiting
Mass Balance Clinical Trial With TEV-56286
Start: Oct 2024Est. completion: Nov 20248 patients
Phase 1Completed
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
Start: Jul 2022Est. completion: Sep 202740 patients
Phase 1Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 1,019 patients
4 companies competing in this space